An Open-Label Study Evaluating the Safety and Tolerability of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Next Previous
Trial Profile

An Open-Label Study Evaluating the Safety and Tolerability of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs VC 02 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors ViaCyte

    • Most Recent Events

    • 03 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 07 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 26 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top